Trial Profile
Rituximab (IDEC-C2B8) Plus GM-CSF in Patients With Follicular B-Cell Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Sargramostim (Primary)
- Indications Follicular lymphoma
- Focus Therapeutic Use
- 21 Sep 2013 New source identified and integrated (M.D. Anderson Cancer Center; DM98-304).
- 20 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Sep 2013 New trial record